Landos Biopharma Initiates Ph I Trial of First-in-class Oral Treatment for IBD

July 12, 2018
  • BT-11 is a first-in-class, oral, locally-acting small molecule
  • BT-11 has demonstrated a 90% reduction of inflammation by acting locally in the gut mucosa in 4 validated mouse models
  • Landos has 6 additional candidates in development for other conditions


Landos Biopharma, Inc announced on 7/12/2018 that the first healthy subjects have been dosed in a Phase 1 clinical study of BT-11, a first-in-class, orally-administered, molecule targeting the LANCL2 pathway. The Phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD).

“We raised our Series A round in September 2017 to finance the completion of the IND-enabling studies and Phase 1 clinical testing. The FDA accepted Landos’ IND for BT-11 in June, and the dosing of the first subject cohort confirms that we have effectively executed that plan. Launching this trial marks a significant milestone for Landos and represents the next step in confirming the safety and effectiveness of BT-11 which has the potential to greatly impact the treatment options of millions of people afflicted by IBD around the world,” said Dr. Josep Bassaganya-Riera, Chairman and CEO of Landos. “Despite current treatments, there remains an unmet clinical need for chronic therapies for UC and CD with improved safety and tolerability.”

BT-11 has demonstrated a 90% reduction of inflammation by acting locally in the gut mucosa in 4 validated mouse models of IBD at doses of 8 mg/kg/d. It has also demonstrated excellent human translation in in vitro human translational studies with cells from Crohn’s disease patients.

 BT-11 is a first-in-class, oral, locally-acting small molecule targeted to the gastrointestinal tract for treatment of inflammatory bowel disease. BT-11 has demonstrated safety and efficacy in multiple preclinical models, with safety and tolerability evaluation underway in a Phase 1 clinical study. BT-11 intercepts IBD by activating the LANCL2 pathway, decreasing the production of key inflammatory mediators and increasing anti-inflammatory molecules within the gastrointestinal tract.

In addition to BT-11, Landos has six other candidates in development. The other candidates are intended to treat a number of conditions including type 1 and type 2 diabetes and rheumatoid arthritis.



CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.